li001

Interim results show that combining axatilimab with ruxolitinib appears safe and well tolerated as a first-line treatment for moderate-to-severe chronic graft-versus-host disease. The study tested this combination because the two drugs work in different ways. Axatilimab targets immune cells that drive fibrosis, while ruxolitinib reduces inflammation by blocking cytokine signaling. Patients were assigned to receive […]

Updated results show that adagrasib works differently in patients with KRAS G12C–mutated non–small cell lung cancer depending on their overall health and functional status. In older patients who were still in good condition (performance status 0–1), the drug showed meaningful benefits. About 31% of patients responded to treatment, with cancer controlled for a median of

Results show that relugolix works well and is safe for patients with advanced prostate cancer in real-world use, whether taken alone or with other treatments. In the first six months, patients maintained a stable quality of life, with no major decline reported in both single-drug and combination therapy groups. Most patients followed their treatment closely,

The National Comprehensive Cancer Network has adopted a new risk model from the International Bladder Cancer Group to better classify patients with intermediate-risk non–muscle-invasive bladder cancer. Instead of treating all patients the same way, this approach helps doctors decide who needs more aggressive treatment and who can receive less intensive care. The model looks at